SCM and Allele: iPSC-based Diabetes Drug Development

SCM Lifescience to in-license iPSCs-based diabetes drug from U.S. firm – Pulse by Maeil Business News Korea July 02, 2021, Seoul SCM Lifescience has agreed to in-license a diabetes drug using pancreatic beta cells derived from induced pluripotent stem cells (iPSCs) from San Diego-based Allele Biotechnology and Pharmaceuticals, the South Korean stem cell therapy developer…

Allele cGMP iPSC Protocol Published in Current Protocols

Allele Discloses How its Highly Efficient iPSC Culturing is Conducted Under cGMP July 14, 2020 06:00 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–In their latest paper published in the online prepublication by the peer-reviewed journal Current Protocols, scientists and cGMP operation managers at Allele Biotechnology present a series of step-by-step protocols for manufacturers of iPSC (induced…